Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSC835 in Hematological Malignancies Undergoing UCB Transplantation
NCT01930162Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spanlecortemlocel in acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL) and 2 more, sponsored by Novartis. Primary endpoint: Absence of Graft Failure at Day 42. Started Oct 2014; status: completed.
02
Drugs
spanlecortemlocel
03
Conditions
acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01930162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01930162.